Meeting News CoverageVideo

VIDEO: Expert recaps three trials in gastric, esophageal cancer

SAN FRANCISCO — Daniel V. T. Catenacci, MD, a GI medical oncologist at the University of Chicago, recaps his discussion following the presentation of three abstracts at the Gastrointestinal Cancers Symposium.

“The first was called the NEOSCOPE trial, which was an induction chemotherapy trial followed by a randomization to two different chemotherapies with radiation prior to surgery. … The carboplatin/paclitaxel [arm] met the primary endpoint of having at least 10 of the first 38 patients going to surgery,” he said.

“The second one was an anti-angiogenesis abstract in the first-line setting of metastatic disease with aflibercept with FOLFOX or placebo. It was unfortunately a negative trial,” he said.

“The third trial was probably the most important and significant because it was a large randomized phase 3 trial called the GATSBY trial that was looking at second-line therapy with T-DM1 compared to a control arm of a taxane … in patients that were chemorefractory in the first-line setting,” he said. “The trial in the second-line with T-DM1 was negative.”

Disclosures: Catenacci reports honoraria from Amgen, Foundation Medicine, Genentech/Roche, Genmab, Lilly, OncoPlex Diagnostics and Taiho Pharmaceutical; consulting or advisory roles with Amgen, Genentech/Roche and OncoPlex Diagnostics; speakers’ bureau roles with Foundation Medicine, Lilly and OncoPlex Diagnostics; and research funding from Amgen, Genentech and OncoPlex Diagnostics.

SAN FRANCISCO — Daniel V. T. Catenacci, MD, a GI medical oncologist at the University of Chicago, recaps his discussion following the presentation of three abstracts at the Gastrointestinal Cancers Symposium.

“The first was called the NEOSCOPE trial, which was an induction chemotherapy trial followed by a randomization to two different chemotherapies with radiation prior to surgery. … The carboplatin/paclitaxel [arm] met the primary endpoint of having at least 10 of the first 38 patients going to surgery,” he said.

“The second one was an anti-angiogenesis abstract in the first-line setting of metastatic disease with aflibercept with FOLFOX or placebo. It was unfortunately a negative trial,” he said.

“The third trial was probably the most important and significant because it was a large randomized phase 3 trial called the GATSBY trial that was looking at second-line therapy with T-DM1 compared to a control arm of a taxane … in patients that were chemorefractory in the first-line setting,” he said. “The trial in the second-line with T-DM1 was negative.”

Disclosures: Catenacci reports honoraria from Amgen, Foundation Medicine, Genentech/Roche, Genmab, Lilly, OncoPlex Diagnostics and Taiho Pharmaceutical; consulting or advisory roles with Amgen, Genentech/Roche and OncoPlex Diagnostics; speakers’ bureau roles with Foundation Medicine, Lilly and OncoPlex Diagnostics; and research funding from Amgen, Genentech and OncoPlex Diagnostics.

    See more from Gastrointestinal Cancers Symposium